We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.
Kevin Strange discussed his company, Novo Biosciences, and how it is developing small molecules that restore the body’s ability to regenerate. He went into detail about how humans begin life with this ability but lose it as they age. He discussed MSI-1436, which is a prospective drug for reversing ischemic heart injury and making life easier for survivors of heart attack as well as reversing skeletal muscle degeneration.
Comments are closed.